Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

49
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishment of a prognostic score for distant recurrence in follicular thyroid carcinoma.

Endocrine journal·2026
Same author

Clinical predictors of TRAb decline after total thyroidectomy in patients with Graves' disease.

European thyroid journal·2025
Same author

Active surveillance for small papillary thyroid carcinoma.

Endocrine-related cancer·2025
Same author

The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.

Endocrine journal·2025
Same author

Establishment of novel prognostic groups for papillary thyroid carcinoma using a modified risk classification based on tumor extension in the guidelines of the Japan Association of Endocrine Surgery.

Endocrine journal·2025
Same author

Management of thyroid tumors diagnosed cytologically as follicular neoplasms in a high-volume center: utility of a scoring system using serum thyroglobulin level, tumor size, ultrasound testing, and cytological diagnosis.

Endocrine journal·2024

Related Experiment Video

Updated: May 6, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

911

Prognostic factors evaluated in differentiated thyroid carcinomas.

Yasuhiro Ito, Akira Miyauchi

    Endocrine Connections
    |December 16, 2025
    PubMed
    Summary
    This summary is machine-generated.

    Prognostic factors for papillary (PTC) and follicular thyroid carcinomas (FTC) differ. Accurate evaluation of these markers aids in predicting outcomes and guiding treatment for differentiated thyroid cancer.

    Keywords:
    differentiated thyroid carcinomadynamicfollicular carcinomapapillary carcinomaprognostic factorsstatic

    More Related Videos

    Spontaneous Murine Model of Anaplastic Thyroid Cancer
    05:39

    Spontaneous Murine Model of Anaplastic Thyroid Cancer

    Published on: February 3, 2023

    2.2K
    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.2K

    Related Experiment Videos

    Last Updated: May 6, 2026

    Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
    03:55

    Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

    Published on: June 9, 2023

    911
    Spontaneous Murine Model of Anaplastic Thyroid Cancer
    05:39

    Spontaneous Murine Model of Anaplastic Thyroid Cancer

    Published on: February 3, 2023

    2.2K
    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.2K

    Area of Science:

    • Endocrinology
    • Oncology
    • Pathology

    Background:

    • Differentiated thyroid carcinoma encompasses papillary (PTC) and follicular thyroid carcinomas (FTC), each with distinct biological behaviors and prognostic factors.
    • PTC is typically diagnosed via cytology, with tumor size, lymph node metastasis, and extrathyroidal/extranodal invasion impacting disease recurrence-free survival (DFS) and cause-specific survival (CSS).
    • FTC diagnosis relies on postoperative pathology, where age and tumor size are linked to prognosis, and invasiveness (minimally, angioinvasive, widely) is a key determinant.

    Purpose of the Study:

    • To delineate the differing prognostic factors for papillary and follicular thyroid carcinomas.
    • To highlight the importance of various clinical, pathological, and molecular markers in predicting outcomes for differentiated thyroid cancer.
    • To emphasize the need for comprehensive prognostic evaluation throughout patient management.

    Main Methods:

    • Review and synthesis of existing literature on prognostic factors in PTC and FTC.
    • Analysis of clinical indicators such as age, tumor size, and metastasis.
    • Evaluation of pathological features including tumor invasion, variant types, Ki-67 index, and gene mutations (TERT).

    Main Results:

    • For PTC, significant prognostic factors include tumor size, lymph node metastasis, extrathyroidal/extranodal invasion, age, aggressive variants, Ki-67 index, and TERT promoter mutations.
    • For FTC, age and tumor size are associated with poor prognosis, and the degree of angioinvasion is critical, with capsular invasion being less significant than vascular invasion.
    • Dynamic markers (thyroglobulin doubling rate, metastatic tumor volume-doubling rate) and immunological indicators (neutrophil-to-lymphocyte ratio) show utility in prognosis and treatment evaluation.

    Conclusions:

    • Prognostic marker evaluation differs significantly between PTC and FTC, necessitating tailored assessment.
    • Accurate pre-, intra-, and postoperative evaluation of prognostic markers is crucial for optimizing patient management and treatment strategies for differentiated thyroid cancer.
    • Advanced markers, including dynamic and immunological indicators, offer valuable insights for predicting prognosis and monitoring treatment response.